Primaquine

DB01087

small molecule approved

Deskripsi

An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Struktur Molekul 2D

Berat 259.3467
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 3.7-7.4 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food. Food decreases irritation.

Interaksi Obat

1246 Data
Deferasirox The serum concentration of Primaquine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Primaquine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Primaquine can be decreased when it is combined with Teriflunomide.
Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Primaquine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Primaquine.
Everolimus The metabolism of Everolimus can be decreased when combined with Primaquine.
Flibanserin The metabolism of Flibanserin can be decreased when combined with Primaquine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Primaquine.
Ivabradine The metabolism of Ivabradine can be decreased when combined with Primaquine.
Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Primaquine.
Lurasidone The metabolism of Lurasidone can be decreased when combined with Primaquine.
Naloxegol The metabolism of Naloxegol can be decreased when combined with Primaquine.
Olaparib The metabolism of Olaparib can be decreased when combined with Primaquine.
Ranolazine The metabolism of Ranolazine can be decreased when combined with Primaquine.
Sonidegib The metabolism of Sonidegib can be decreased when combined with Primaquine.
Avanafil The metabolism of Avanafil can be decreased when combined with Primaquine.
Eplerenone The metabolism of Eplerenone can be decreased when combined with Primaquine.
Artemether The risk or severity of QTc prolongation can be increased when Primaquine is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Lumefantrine.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Primaquine.
Colchicine The metabolism of Colchicine can be decreased when combined with Primaquine.
Fentanyl The metabolism of Fentanyl can be decreased when combined with Primaquine.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Primaquine.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Primaquine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Primaquine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Primaquine.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Primaquine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Primaquine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Primaquine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Primaquine is combined with Prilocaine.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Primaquine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Primaquine.
Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Primaquine.
Mefloquine The risk or severity of adverse effects can be increased when Primaquine is combined with Mefloquine.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Primaquine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Primaquine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Primaquine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Primaquine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Primaquine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Primaquine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Primaquine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Primaquine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Primaquine.
Abiraterone The serum concentration of Primaquine can be increased when it is combined with Abiraterone.
Cyproterone acetate The metabolism of Primaquine can be increased when combined with Cyproterone acetate.
Thiethylperazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Thiethylperazine.
Triflupromazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Triflupromazine.
Fluphenazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Fluphenazine.
Moricizine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Moricizine.
Trifluoperazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Trifluoperazine.
Acetophenazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Acetophenazine.
Alimemazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Alimemazine.
Periciazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Periciazine.
Acepromazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Acepromazine.
Aceprometazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Aceprometazine.
Thioproperazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Thioproperazine.
BL-1020 The risk or severity of QTc prolongation can be increased when Primaquine is combined with BL-1020.
Cyamemazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Cyamemazine.
Propiopromazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Propiopromazine.
Perazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Perazine.
Butaperazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Butaperazine.
Chlorproethazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Chlorproethazine.
Thiazinam The risk or severity of QTc prolongation can be increased when Primaquine is combined with Thiazinam.
Dixyrazine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Dixyrazine.
Perphenazine enanthate The risk or severity of QTc prolongation can be increased when Primaquine is combined with Perphenazine enanthate.
Dapsone The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Primaquine.
Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Primaquine.
Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Primaquine.
Ouabain The serum concentration of Ouabain can be increased when it is combined with Primaquine.
Oleandrin The serum concentration of Oleandrin can be increased when it is combined with Primaquine.
Cymarin The serum concentration of Cymarin can be increased when it is combined with Primaquine.
Proscillaridin The serum concentration of Proscillaridin can be increased when it is combined with Primaquine.
Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with Primaquine.
Gitoformate The serum concentration of Gitoformate can be increased when it is combined with Primaquine.
Peruvoside The serum concentration of Peruvoside can be increased when it is combined with Primaquine.
Metildigoxin The serum concentration of Metildigoxin can be increased when it is combined with Primaquine.
Anagrelide The risk or severity of QTc prolongation can be increased when Primaquine is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Primaquine is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Primaquine is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Primaquine is combined with Valproic acid.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Primaquine is combined with Grepafloxacin.
Toremifene The risk or severity of QTc prolongation can be increased when Primaquine is combined with Toremifene.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Primaquine is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Primaquine is combined with Mifepristone.
Cocaine The risk or severity of methemoglobinemia can be increased when Primaquine is combined with Cocaine.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Primaquine is combined with Arsenic trioxide.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Primaquine is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Halofantrine.
Lithium cation The risk or severity of QTc prolongation can be increased when Primaquine is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Primaquine is combined with Temafloxacin.
Asenapine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Asenapine.
Glasdegib The risk or severity of QTc prolongation can be increased when Primaquine is combined with Glasdegib.
Macimorelin The risk or severity of QTc prolongation can be increased when Primaquine is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Primaquine is combined with Terodiline.
Cisapride The risk or severity of QTc prolongation can be increased when Primaquine is combined with Cisapride.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Primaquine.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Primaquine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Primaquine.

Target Protein

Fe(II)-protoporphyrin IX
Keratin, type II cytoskeletal 7 KRT7
Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 4027117
    Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM: Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985 Jun;19(6):745-50.
  • PMID: 13242948
    ALVING AS, ARNOLD J, HOCKWALD RS, CLAYMAN CB, DERN RJ, BEUTLER E, FLANAGAN CL: Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955 Aug;46(2):301-6.
  • PMID: 16968913
    Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15.
  • PMID: 5686480
    Cohen RJ, Sachs JR, Wicker DJ, Conrad ME: Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968 Nov 21;279(21):1127-31.
  • PMID: 8828017
    Coleman MD, Coleman NA: Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996 Jun;14(6):394-405.
  • PMID: 11181487
    Taavitsainen P, Juvonen R, Pelkonen O: In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos. 2001 Mar;29(3):217-22.
  • PMID: 12451431
    Bapiro TE, Andersson TB, Otter C, Hasler JA, Masimirembwa CM: Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42. Epub 2002 Oct 2.

Contoh Produk & Brand

Produk: 15 • International brands: 2
Produk
  • Primaquine
    Tablet • 26.3 mg • Oral • Canada • Approved
  • Primaquine Phosphate
    Tablet, film coated • 15 mg/1 • Oral • US • Approved
  • Primaquine Phosphate
    Tablet • 15 mg/1 • Oral • US • Generic • Approved
  • Primaquine Phosphate
    Tablet, film coated • 15 mg/1 • Oral • US • Generic • Approved
  • Primaquine Phosphate
    Tablet • 15 mg/1 • Oral • US • Generic • Approved
  • Primaquine Phosphate
    Tablet, film coated • 15 mg/1 • Oral • US • Generic • Approved
  • Primaquine Phosphate
    Tablet, film coated • 15 mg/1 • Oral • US • Generic • Approved
  • Primaquine Phosphate
    Tablet, film coated • 15 mg/1 • Oral • US • Approved
Menampilkan 8 dari 15 produk.
International Brands
  • Neo-Quipenyl
  • Primachin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul